Amprion is passionate about improving patient care through clinical diagnostics and our Biopharma partnerships. We are focused on neurodegenerative diseases and believe in doing our best for patients and patient care.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:
Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.
The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.
For additional information, please visit our billing page.
